Biguanides (BG) — Competitive Intelligence Brief

Biguanides (BG) (Biguanides (BG)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Biguanide. Area: Diabetes.

phase 3 Biguanide AMPK, mitochondrial complex I Diabetes Small molecule

Target snapshot

Biguanides (BG) (Biguanides (BG)) — Eli Lilly and Company. Biguanides reduce hepatic glucose production and improve insulin sensitivity by activating AMP-activated protein kinase (AMPK) and inhibiting mitochondrial glycerol-3-phosphate dehydrogenase.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Biguanides (BG) TARGET	Biguanides (BG)	Eli Lilly and Company	phase 3	Biguanide	AMPK, mitochondrial complex I
Biguanide (BG)	Biguanide (BG)	Eli Lilly and Company	phase 3	Biguanide	AMPK, mitochondrial complex I
Glimepiride/metformin fixed combination	Glimepiride/metformin fixed combination	Handok Inc.	marketed	Sulfonylurea/biguanide combination	ATP-sensitive potassium channel (glimepiride); mitochondrial complex I / AMPK pathway (metformin)
semaglutide combined with metformin	semaglutide combined with metformin	The First Affiliated Hospital of Xiamen University	marketed	GLP-1 receptor agonist combined with biguanide	GLP-1R; AMPK pathway
MET + Vildagliptin Group	MET + Vildagliptin Group	Hospital de Clinicas de Porto Alegre	marketed	Combination antidiabetic agent (biguanide + DPP-4 inhibitor)	Metformin: mitochondrial glycerophosphate dehydrogenase; Vildagliptin: DPP-4 (dipeptidyl peptidase-4)
Glucophage tablets and Victoza	Glucophage tablets and Victoza	University Medical Centre Ljubljana	marketed	Biguanide (metformin) and GLP-1 receptor agonist (liraglutide)	AMP-activated protein kinase (metformin); GLP-1 receptor (liraglutide)
Telmisartan plus Metformin	Telmisartan plus Metformin	Third Military Medical University	marketed	ARB + Biguanide combination	Angiotensin II type 1 receptor (AT1R); mitochondrial glycerophosphate dehydrogenase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Biguanide class)

1. AstraZeneca · 4 drugs in this class
2. Merck Sharp & Dohme LLC · 3 drugs in this class
3. University of Texas Southwestern Medical Center · 2 drugs in this class
4. Mount Sinai Hospital, Canada · 2 drugs in this class
5. GlaxoSmithKline · 2 drugs in this class
6. Eli Lilly and Company · 2 drugs in this class
7. University Magna Graecia · 2 drugs in this class
8. First Affiliated Hospital of Wenzhou Medical University · 1 drug in this class
9. Ente Ospedaliero Ospedali Galliera · 1 drug in this class
10. Daewoong Pharmaceutical Co. LTD. · 1 drug in this class